Latest CGEM news

Biotech Stocks Dive As Top 2% Names Take Hardest Hit

Investors Business Daily · Wed, 23 Sep 2026 12:49:51 -0400

Biotech stocks widely slumped Wednesday, with Rapport Therapeutics, Climb Bio and Cullinan Therapeutics among some of the hardest-hit names.

Cullinan Therapeutics to Participate in the Stifel 2026 Virtual Immunology and Inflammation Forum

GlobeNewsWire · Mon, 21 Sep 2026 12:00:00 -0400

CAMBRIDGE, Mass., Sept. 21, 2026 (GLOBE NEWSWIRE) -- Cullinan Therapeutics, Inc. (Nasdaq: CGEM; “Cullinan”), a clinical-stage biopharmaceutical company accelerating potential first- or best-in-class, disease-modifying T cell engagers in autoimmune diseases and cancer, today announced that Nadim Ahmed, Chief Executive Officer, and Jeffrey Jones, M.D., M.B.A., Chief Medical Officer, will participate in a fireside chat at the Stifel 2026 Virtual Immunology and Inflammation Forum on Thursday, September 24, 2026, at 1:30 p.m. ET.

Cullinan Therapeutics, Inc. (CGEM) Shareholder/Analyst Call Transcript

Seeking Alpha · Mon, 14 Sep 2026 12:31:41 -0400

Cullinan Therapeutics, Inc. (CGEM) Shareholder/Analyst Call Transcript

Cullinan Therapeutics to Host Virtual Analyst and Investor Event Today to Feature Zipalertinib Plus Chemotherapy Phase 3 REZILIENT3 Data Presented at the IASLC 2026 World Conference on Lung Cancer

GlobeNewsWire · Mon, 14 Sep 2026 07:00:00 -0400

CAMBRIDGE, Mass., Sept. 14, 2026 (GLOBE NEWSWIRE) -- Cullinan Therapeutics, Inc. (Nasdaq: CGEM), a clinical-stage biopharmaceutical company accelerating potential first- or best-in-class, disease-modifying T cell engagers in autoimmune diseases and cancer, today announced that it will host a virtual event for analysts and institutional investors today at 8:00 a.m.

Zipalertinib Plus Chemotherapy Demonstrates 6-Month Median Progression-Free Survival Benefit in REZILIENT3 Phase 3 Trial in First-Line EGFR Exon 20 Insertion Mutation Non-Small Cell Lung Cancer

Business Wire · Sun, 13 Sep 2026 19:15:00 -0400

PRINCETON, N.J. & TOKYO & CAMBRIDGE, Mass.--(BUSINESS WIRE)--Taiho Oncology, Inc., Taiho Pharmaceutical Co., Ltd., and Cullinan Therapeutics, Inc. (Nasdaq: CGEM) today announced results from the Phase 3 REZILIENT3 trial evaluating zipalertinib plus chemotherapy versus chemotherapy alone in the first-line treatment of patients with epidermal growth factor receptor (EGFR) exon 20 insertion (ex20ins) mutation-positive non-small cell lung cancer (NSCLC). The data were presented at the International.

Cullinan Therapeutics to Host Virtual Analyst and Investor Event to Showcase Zipalertinib Plus Chemotherapy Phase 3 REZILIENT3 Data Presented at the IASLC 2026 World Conference on Lung Cancer

GlobeNewsWire · Thu, 10 Sep 2026 13:00:00 -0400

Results from the planned interim analysis of the Phase 3 REZILIENT3 trial of zipalertinib plus chemotherapy in first-line EGFR exon 20 insertion mutation NSCLC to be presented in Presidential Symposium 2 on Sunday, September 13, 2026

Cullinan Therapeutics: A Self-Funding Bridge To Immune Reset

Seeking Alpha · Wed, 26 Aug 2026 05:41:12 -0400

Cullinan Therapeutics offers a unique, multi-asset portfolio with near-, mid-, and long-term value drivers, reducing reliance on external funding. Zipalertinib's positive Phase 3 results and upcoming regulatory milestones provide a potential funding bridge for advancing CGEM's autoimmune and oncology platforms. CLN-049's accelerated regulatory path in AML and CLN-978's promising early autoimmune data position CGEM for multiple commercialization opportunities.

Market information is provided for research and visualization and is not investment advice.